Advertisement

InVivo Therapeutics Corp., a Cambridge spinal cord injury treatment developer, has completed a reverse merger and initiated a $10.5 million private placement offering.

The reverse merger was conducted with InVivo Therapeutics Holdings Corp., with the holding company operating InVivo Therapeutics as a wholly-owned subsidary and quoted on the Over-the-Counter market under the ticker symbol “NVIV.” InVivo Therapeutics’ current management team will retain their positions in the subsidiary. As part of the merger, 31.6 million shares of the holding company’s common stock were offered to InVivo Therapeutics shareholders.

SOURCE

Advertisement
Advertisement